FASLG Antibody

What is FASLG and why do researchers study it?

FASLG (Fas ligand, also known as CD178) is a 281-amino acid protein belonging to the Tumor Necrosis Factor (TNF) family. It plays critical roles in immune regulation and apoptotic signaling pathways. FASLG has multiple cellular localizations including nuclear, membrane-associated, and secreted forms, with several reported glycosylation sites . Researchers study FASLG because of its fundamental importance in cytokine signaling, immune system function, and its implications in various disease processes, including cancer, autoimmune disorders, and inflammatory conditions.

What are the key characteristics of commercially available FASLG antibodies?

Commercial FASLG antibodies are available in multiple formats with varying specifications:

Based on available data, over 390 FASLG antibodies are currently available from 27 different suppliers, offering researchers a wide range of options for different experimental approaches .

How can I determine which FASLG antibody clone is most suitable for my research?

When selecting a FASLG antibody clone, consider these methodological factors:

• Review validation data specific to your application (WB, FCM, IHC, IF, ELISA)

• Examine epitope information - some antibodies target specific domains of FASLG

• Check published literature for successfully used clones in similar experiments

• Consider the binding kinetics, particularly off-rates for applications like IP-MS

• Validate specificity through proper controls

For instance, when studying protein interactions, antibodies with slow off-rates are preferable as they better retain binding during stringent washing steps in procedures like immunoprecipitation . The antibody's binding epitope can also be critical—some epitopes may be masked by protein-protein interactions or post-translational modifications in cellular contexts.

What are the recommended protocols for optimizing FASLG antibody use in Western blotting?

For optimal Western blotting with FASLG antibodies:

• Sample preparation: Use fresh lysates with protease inhibitors to prevent degradation of FASLG protein

• Antibody dilution: Start with manufacturer recommendations (typically 1:500-1:2000 for FASLG antibodies)

• Blocking optimization:

  • Use 5% non-fat dry milk or BSA in TBST

  • For phospho-specific detection, BSA is preferred over milk

• Incubation conditions:

  • Primary antibody: Overnight at 4°C

  • Secondary antibody: 1 hour at room temperature

• Controls:

  • Positive control: Cell lines known to express FASLG

  • Negative control: FASLG-knockout cells or tissues

  • Loading control: β-actin, GAPDH, or other housekeeping proteins

The expected molecular weight for FASLG is approximately 31.5 kDa , though observed weights may vary due to post-translational modifications, particularly glycosylation.

How should I approach FASLG antibody validation in my experimental system?

A robust validation approach for FASLG antibodies includes:

• Specificity testing:

  • Cross-reactivity assessment against related proteins

  • Comparing multiple antibodies targeting different epitopes

  • Using genetic knockdown/knockout controls

• Application-specific validation:

  • For IP-MS: Verify that FASLG provides the highest normalized spectral abundance factor (NSAF) value

  • For IF/IHC: Compare staining patterns with known FASLG localization

  • For flow cytometry: Compare with isotype controls and blocking peptides

• Advanced validation strategies:

  • Peptide competition assays using FASLG-derived peptides (e.g., amino acids 101-150)

  • Orthogonal method confirmation (e.g., validate WB findings with IF)

A comprehensive validation should demonstrate that the antibody binds specifically to FASLG in your experimental conditions and can reliably detect the protein at physiological expression levels.

What are the key considerations for using FASLG antibodies in flow cytometry?

Flow cytometry with FASLG antibodies requires careful attention to:

• Sample preparation:

  • Use gentle fixation to preserve FASLG epitopes

  • Optimize permeabilization if detecting intracellular FASLG

• Antibody selection:

  • Consider directly conjugated antibodies (e.g., FITC-conjugated anti-FASL) for simplicity

  • Verify conjugate compatibility with your cytometer configuration

• Titration and controls:

  • Perform antibody titration to determine optimal concentration

  • Include:

    • Isotype controls matched to primary antibody

    • FMO (fluorescence minus one) controls

    • Positive and negative cell populations

• Analysis considerations:

  • Be aware that FASLG can exist in membrane-bound and soluble forms

  • Expression levels may vary significantly between cell types and activation states

  • Multicolor panels should be designed with appropriate compensation controls

Commercial options like the anti-FASL monoclonal antibody clone MFL4 (FITC-conjugated) are specifically validated for flow cytometry applications and detect mouse and rat FASLG .

Why might I see non-specific binding with my FASLG antibody and how can I resolve it?

Non-specific binding with FASLG antibodies may occur for several reasons:

• Cross-reactivity issues:

  • FASLG shares structural similarities with other TNF family members

  • Solution: Use antibodies verified for specificity against other TNF family proteins

• Suboptimal blocking:

  • Insufficient blocking allows antibody binding to non-target proteins

  • Solution: Optimize blocking reagent (BSA, milk, serum) and increase blocking time

• Excessive antibody concentration:

  • Increases background signal

  • Solution: Perform titration experiments to determine optimal concentration

• Sample quality issues:

  • Protein degradation can create fragments recognized by antibody

  • Solution: Use fresh samples with appropriate protease inhibitors

• Detection system problems:

  • High-sensitivity substrates can amplify background

  • Solution: Adjust exposure times or switch to less sensitive detection system

Methodologically, verifying specificity through multiple antibodies targeting different FASLG epitopes can help confirm true signals versus non-specific binding artifacts.

How should I store and handle FASLG antibodies to maintain their performance?

Proper storage and handling of FASLG antibodies is critical for maintaining their performance:

• Long-term storage:

  • Store at -20°C for up to one year

  • Avoid repeated freeze-thaw cycles

• Working stock handling:

  • For frequent use, aliquot and store at 4°C for up to one month

  • Add preservatives like sodium azide (0.02%) if not already present

• Formulation considerations:

  • Most commercial FASLG antibodies are supplied in PBS containing 50% glycerol, 0.5% BSA, and 0.02% sodium azide

  • This formulation helps maintain stability

• Reconstitution (if applicable):

  • Follow manufacturer's instructions precisely

  • Reconstitute only the amount needed

  • Store reconstituted antibody in small aliquots

• Tracking antibody performance:

  • Document lot numbers and performance

  • Include positive controls across experiments to monitor antibody activity over time

Proper handling significantly influences experimental reproducibility—degraded antibodies can lead to inconsistent results and false negatives.

What approaches can help resolve contradictory results between different applications using the same FASLG antibody?

When facing contradictory results across applications with the same FASLG antibody:

• Consider epitope accessibility differences:

  • Some epitopes may be masked in native conditions (IF/IHC) but exposed in denatured states (WB)

  • Solution: Try antibodies targeting different epitopes of FASLG

• Evaluate fixation and preparation effects:

  • Different fixatives modify protein structure differently

  • Solution: Test multiple fixation protocols with appropriate controls

• Assess antibody performance in each application:

  • An antibody may perform well in WB but poorly in IHC

  • Solution: Verify antibody validation data for each specific application

• Consider protein complex formation:

  • FASLG functions in protein complexes that may affect antibody binding

  • Solution: Use detergents or conditions that disrupt protein-protein interactions

• Methodological approach to resolution:

  • Perform orthogonal validation with multiple techniques

  • Use genetic approaches (siRNA, CRISPR) to confirm antibody specificity

  • Consider using multiple antibodies against different FASLG epitopes

Remember that the binding epitope of antibodies is often unknown, and some may target epitopes that are blocked in cell lysates due to protein interactions or post-translational modifications .

How can FASLG antibodies be employed in co-immunoprecipitation studies to identify interaction partners?

FASLG antibodies can be powerful tools for studying protein interactions through co-immunoprecipitation (co-IP):

• Antibody selection for co-IP:

  • Choose antibodies with slow off-rates for stable binding during washing steps

  • Verify the antibody doesn't interfere with known interaction domains

• Methodological considerations:

  • Use gentle lysis conditions to preserve protein-protein interactions

  • Consider crosslinking to stabilize transient interactions

  • Optimize salt and detergent concentrations in wash buffers

• Validation approach:

  • Perform IP-MS validation to ensure antibody captures endogenous FASLG

  • Consider "gold standard" criteria where the target protein provides the highest normalized spectral abundance factor (NSAF)

• Control experiments:

  • IgG isotype control to identify non-specific interactions

  • Reverse co-IP to confirm interactions

  • Input control to verify protein expression

• Analysis considerations:

  • Use gentle elution methods to maintain complex integrity

  • Consider size-exclusion chromatography to analyze complex formation

  • Confirm interactions with orthogonal methods (e.g., proximity ligation assay)

The complex formed by FASLG with other proteins can provide insights into signaling pathways and regulatory mechanisms relevant to understanding its role in health and disease.

What approaches can researchers use to study post-translational modifications of FASLG using antibodies?

Studying post-translational modifications (PTMs) of FASLG requires specialized approaches:

• Antibody selection strategies:

  • Use modification-specific antibodies (e.g., phospho-FASLG, glycosylated FASLG)

  • Pair with total FASLG antibodies to determine modification stoichiometry

• Enrichment methods:

  • Immunoprecipitate FASLG first, then probe for modifications

  • Use modification-specific enrichment (e.g., phosphopeptide enrichment) followed by FASLG detection

• Advanced analytical approaches:

  • Combine immunoprecipitation with mass spectrometry (IP-MS)

  • Use Phos-tag gels to separate phosphorylated forms

  • Apply 2D gel electrophoresis to separate differentially modified forms

• Experimental controls:

  • Treatment with modification-removing enzymes (phosphatases, deglycosylases)

  • Inhibitors of modification pathways

  • Mutation of known modification sites

• Methodological considerations:

  • Different lysis buffers maintain different PTMs

  • Include modification-preserving inhibitors during sample preparation

  • Consider site-specific antibodies for known modification sites

FASLG has reported glycosylation sites that can affect its function, localization, and stability, making the study of these modifications particularly relevant to understanding its biological roles.

How can researchers use FASLG antibodies to investigate differential expression across tissues and disease states?

FASLG antibodies enable comparative studies across tissues and disease states:

• Experimental design considerations:

  • Match sample types and preparation methods for valid comparisons

  • Include appropriate tissue/disease controls

  • Consider using tissue microarrays for high-throughput screening

• Quantitative approaches:

  • Use quantitative Western blotting with standard curves

  • Apply digital pathology tools for IHC quantification

  • Consider flow cytometry for single-cell resolution in complex tissues

• Antibody validation for comparative studies:

  • Verify linear detection range across expected expression levels

  • Ensure consistent performance across different tissue types

  • Include spike-in controls to normalize across experiments

• Controls for reliable comparison:

  • Use the same antibody lot across all samples

  • Include internal reference standards

  • Normalize to appropriate loading controls

• Advanced methodological approaches:

  • Multiplex immunofluorescence to correlate FASLG with other markers

  • Single-cell analysis to detect population heterogeneity

  • Spatial transcriptomics combined with protein detection

When investigating disease states, researchers should remember that FASLG expression can vary significantly between cell types and activation states, requiring careful experimental design and appropriate controls.

How are recombinant antibody technologies advancing FASLG research?

Recombinant antibody technologies are transforming FASLG research:

• Advantages of recombinant FASLG antibodies:

  • Consistent performance between lots

  • Defined sequence and structure

  • Possibility for engineering enhanced properties

• Novel formats and applications:

  • Single-chain fragment variables (scFv) for improved tissue penetration

  • Bispecific antibodies targeting FASLG and other pathway components

  • Intrabodies for tracking and manipulating FASLG in living cells

• High-throughput selection approaches:

  • Phage display selections using synthetic human single-chain fragment variable libraries

  • Site-specific biotinylation for efficient screening

• Validation methodologies:

  • Multi-step validation processes including:

    • Initial binding assays (ELISA, HTRF)

    • Specificity testing (suspension bead assays)

    • Affinity ranking and kinetic measurements

    • Functional testing with endogenous proteins

• Open science initiatives:

  • Programs like ULTRA-DD are creating well-validated recombinant antibody toolboxes

  • Public databases storing sequences and validation data

The development of these technologies enables more reproducible research and opens new avenues for studying FASLG biology in increasingly sophisticated ways.

What considerations should researchers make when designing multiplexed experiments involving FASLG antibodies?

Designing multiplexed experiments with FASLG antibodies requires special attention to:

• Antibody compatibility considerations:

  • Select antibodies raised in different host species to avoid cross-reactivity

  • Consider using directly conjugated primary antibodies to simplify protocols

  • Verify spectral compatibility of fluorophores

• Experimental design strategies:

  • Perform single-color controls to establish baseline signals

  • Include compensation controls for flow cytometry and multi-color imaging

  • Design panels with consideration of antigen abundance (pair bright fluorophores with low-abundance targets)

• Technical optimizations:

  • Sequential staining may be necessary to avoid cross-reactivity

  • Optimize antibody concentrations individually before combining

  • Consider signal amplification for low-abundance targets

• Controls for multiplexed experiments:

  • Single-stained controls

  • FMO (fluorescence minus one) controls

  • Isotype controls for each species/isotype

  • Blocking experiments to confirm specificity

• Analysis considerations:

  • Develop strategies for managing spectral overlap

  • Consider computational approaches for teasing apart co-localization

  • Use appropriate statistical methods for correlation analyses

Multiplexed approaches allow researchers to study FASLG in the context of its signaling pathways and interaction networks, providing more comprehensive insights than single-marker studies.